共 153 条
[1]
Siegel RL(2017)Cancer Statistics CA Cancer J Clin 67 7-30
[2]
Miller KD(2005)Endocrine therapy for prostate cancer Acta Oncol 44 605-609
[3]
Jemal A(2015)Androgen deprivation of prostate cancer: leading to a therapeutic dead end Cancer Lett 367 12-17
[4]
Damber JE(2015)Metastatic castration-resistant prostate cancer: time for innovation Future Oncol (Lond, Engl) 11 91-106
[5]
Katzenwadel A(2014)Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 424-433
[6]
Wolf P(2015)Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 16 152-160
[7]
Tucci M(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet (Lond Engl) 376 1147-1154
[8]
Scagliotti GV(2013)Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 213-223
[9]
Vignani F(2010)Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-422
[10]
Beer TM(2008)Cancer-related inflammation Nature 454 436-444